RSV (呼吸器合胞体ウイルス) は、上気道と下気道の両方に軽度の風邪のような症状を引き起こす一般的な呼吸器ウイルスです。RSV は、ほとんどの人は 1 〜 2 週間で回復しますが、特に乳児や高齢者に有害な場合があります。クリーブランド クリニックによると、米国では毎年約 57,000 人の 5 歳未満の子供が RSV に感染しています。大規模な世界的な研究努力と数十年にわたる RSV の標的にもかかわらず、依然として満たされていない重要な医療ニーズが存在します。潜在的な治療薬は、これまで好ましい安全性プロフィールや有効性を証明するのに苦労していました。しかし、RSV ワクチンの開発は過去 10 年間に大きな進歩を遂げました。RSVワクチンおよび抗体市場は、2024年から2030年までに31.65%のCAGRで成長すると予想されます。
約60年にわたる努力の末、生命を脅かすRSウイルス（RSV）に対する効果的なワクチン接種が達成されました。FDAは、GSKのArexvyとファイザーのAbrysvoという2つの新しいRSVワクチンを2023年上半期に承認しました。これらのワクチンは、この感染症に非常に敏感なグループである60歳以上の成人を特に対象としています。これらの商業化と利用可能性は 2024 年までに予想されています。この推定は 2024 年から 2030 年までの期間について行われています。3 つの主要な年齢層すべてを対象とした両方のモダリティ (抗体とワクチン) を考慮すると、世界の RSV ワクチンと抗体市場は次のようになると予想されます。 2024 年には 26 億 1,000 万ドル、2030 年までに 135 億 9,000 万ドルに増加する見込みです。
目次
Table of Contents
1. Executive Summary
2. Introduction
2.1 Respiratory Syncytial Virus (RSV) Vaccine & Antibody: An Overview
2.1.1 Antigenic Subtypes Of Respiratory Syncytial Virus
2.1.2 What went wrong with previous RSV vaccines?
2.1.3 Pre F Protein & It’s Increasing Use in RSV Vaccines
2.2 RSV Vaccine & Antibody (RSV) Segmentation: An Overview
2.2.1 Respiratory Syncytial Virus Vaccine & Antibody Segmentation
3. Global Market Analysis
3.1 Global RSV Vaccine And Antibody Market: An Analysis
3.1.1 Global RSV Vaccine And Antibody Market: An Overview
3.1.2 Global RSV Vaccine And Antibody Market by Value
3.1.3 Global RSV Vaccine And Antibody Market by End User (Adult and Maternal & Pediatric)
3.1.4 Global RSV Vaccine And Antibody Market by Type (Vaccine and Antibody)
3.1.5 Global RSV Vaccine And Antibody Market by Region (The US, Europe and ROW)
3.2 Global RSV Vaccine And Antibody Market: End User Analysis
3.2.1 Global RSV Vaccine And Antibody Market by End User: An Overview
3.2.2 Global Adult RSV Vaccine And Antibody Market by Value
3.2.3 Global Maternal & Pediatric RSV Vaccine And Antibody Market by Value
3.3 Global RSV Vaccine And Antibody Market: Type Analysis
3.3.1 Global RSV Vaccine And Antibody Market by Type: An Overview
3.3.2 Global RSV Vaccine Market by Value
3.3.3 Global RSV Vaccine Market by End User (Adult and Maternal & Pediatric)
3.3.4 Global RSV Vaccine Market by Region (The US, Europe and ROW)
3.3.5 Global RSV Antibody Market by Value
3.3.6 Global RSV Antibody Market by Region
3.4 Global RSV Vaccine Market: End User Analysis
3.4.1 Global RSV Vaccine Market by End User: An Overview
3.4.2 Global Adult RSV Vaccine Market by Value
3.4.3 Global Maternal & Pediatric RSV Vaccine Market by Value
4. Regional Market Analysis
4.1 The US RSV Vaccine And Antibody Market: An Analysis
4.1.1 The US RSV Vaccine And Antibody Market: An Overview
4.1.2 The US RSV Vaccine And Antibody Market by Value
4.1.3 The US RSV Vaccine Market by Value
4.1.4 The US RSV Vaccine Market by End User (Adult and Maternal & Pediatric)
4.1.5 The US Adult RSV Vaccine Market by Value
4.1.6 The US Adult RSV Vaccine Market Product Type by Value
4.1.7 The US Maternal & Pediatric RSV Vaccine Market by Value
4.1.8 The US Maternal & Pediatric RSV Vaccine Market Product Type by Value
4.1.9 The US RSV Antibody Market by Value
4.1.10 The US RSV Antibody Market Product Type by Value
4.2 Europe RSV Vaccine And Antibody Market: An Analysis
4.2.1 Europe RSV Vaccine And Antibody Market: An Overview
4.2.2 Europe RSV Vaccine And Antibody Market by Value
4.2.3 Europe RSV Vaccine Market by Value
4.2.4 Europe RSV Vaccine Market by End User (Adult and Maternal & Pediatric)
4.2.5 Europe Adult RSV Vaccine Market by Value
4.2.6 Europe Adult RSV Vaccine Market Product Type by Value
4.2.7 Europe Maternal & Pediatric RSV Vaccine Market by Value
4.2.8 Europe Maternal & Pediatric RSV Vaccine Market Product Type by Value
4.2.9 Europe RSV Antibody Market by Value
4.2.10 Europe RSV Antibody Market Product Type by Value
4.3 ROW RSV Vaccine And Antibody Market: An Analysis
4.3.1 ROW RSV Vaccine And Antibody Market: An Overview
4.3.2 ROW RSV Vaccine And Antibody Market by Value
4.3.3 ROW RSV Vaccine Market by Value
4.3.4 ROW RSV Vaccine Market by End User (Adult and Maternal & Pediatric)
4.3.5 ROW Adult RSV Vaccine Market by Value
4.3.6 ROW Adult RSV Vaccine Market Product Type by Value
4.3.7 ROW Maternal & Pediatric RSV Vaccine Market by Value
4.3.8 ROW Maternal & Pediatric RSV Vaccine Market Product Type by Value
4.3.9 ROW RSV Antibody Market by Value
4.3.10 ROW RSV Antibody Market Product Type by Value
5. Impact of COVID-19
5.1 Impact of COVID-19
5.1.1 Impact of COVID-19 on Healthcare
5.1.2 Impact of COVID-19 Restrictions on RSV Transmission
5.1.3 Post COVID Scenario
6. Market Dynamics
6.1 Growth Drivers
6.1.1 Rapid Urbanization
6.1.2 Aging Population
6.1.3 Increasing Healthcare Expenditure
6.1.4 Rising Prevalence of Respiratory Syncytial Virus
6.1.5 Greater Unmet Need
6.1.6 Growing Instances of RSV Among Infants
6.1.7 Favorable Government Support
6.2 Challenges
6.2.1 High Cost of Vaccine Development
6.2.2 Inequitable Access to Vaccines
6.3 Market Trends
6.3.1 Use of Artificial Intelligence (AI) in Vaccine and Drug Design
6.3.2 Technological Advancements in Vaccine Administration
6.3.3 Competitive Pipeline
7. Competitive Landscape
7.1 Global RSV Vaccine And Antibody Market: Vaccine & Antibody Candidates
7.2 Global RSV Vaccine And Antibody Players By Market Share
7.3 Global RSV Vaccine And Antibody Market: Current Landscape
8. Company Profiles
8.1 GlaxoSmithKline Plc
8.1.1 Business Overview
8.1.2 Sales by Products
8.1.3 Business Strategies
8.2 Merck & Co., Inc.
8.2.1 Business Overview
8.2.2 Operating Segments
8.2.3 Business Strategies
8.3 Pfizer Inc.
8.3.1 Business Overview
8.3.2 Operating Segments
8.3.3 Business Strategies
8.4 AstraZeneca Plc
8.4.1 Business Overview
8.4.2 Operating Segments
8.4.3 Business Strategies
8.5 Sanofi S.A.
8.5.1 Business Overview
8.5.2 Operating Segments
8.5.3 Business Strategy
8.6 Moderna Inc.
8.6.1 Business Overview
8.6.2 Operating Regions
8.6.3 Business Strategies
8.7 Meissa Vaccines
8.7.1 Business Overview
8.7.2 Business Strategies
8.8 Codagenix
8.8.1 Business Overview
8.8.2 Business Strategies
8.9 Advaccine
8.9.1 Business Overview
List of Figures
Figure 1: Antigenic Subtypes Of Respiratory Syncytial Virus
Figure 2: What went wrong with previous RSV vaccines?
Figure 3: Pre F Protein & It’s Increasing Use in RSV Vaccines
Figure 4: Respiratory Syncytial Virus Vaccine & Antibody Segmentation
Figure 5: Global RSV Vaccine And Antibody Market by Value; 2024-2030 (US$ Billion)
Figure 6: Global RSV Vaccine And Antibody Market by End User; 2024 (Percentage, %)
Figure 7: Global RSV Vaccine And Antibody Market by Type; 2024 (Percentage, %)
Figure 8: Global RSV Vaccine And Antibody Market by Region; 2024 (Percentage, %)
Figure 9: Global Adult RSV Vaccine And Antibody Market by Value; 2024-2030 (US$ Billion)
Figure 10: Global Maternal & Pediatric RSV Vaccine And Antibody Market by Value; 2024-2030 (US$ Billion)
Figure 11: Global RSV Vaccine Market by Value; 2024-2030 (US$ Billion)
Figure 12: Global RSV Vaccine Market by End User; 2024 (Percentage, %)
Figure 13: Global RSV Vaccine Market by Region; 2024 (Percentage, %)
Figure 14: Global RSV Antibody Market by Value; 2024-2030 (US$ Billion)
Figure 15: Global RSV Antibody Market by Region; 2024 (Percentage, %)
Figure 16: Global Adult RSV Vaccine Market by Value; 2024-2030 (US$ Billion)
Figure 17: Global Maternal & Pediatric RSV Vaccine Market by Value; 2024-2030 (US$ Million)
Figure 18: The US RSV Vaccine And Antibody Market by Value; 2024-2030 (US$ Billion)
Figure 19: The US RSV Vaccine Market by Value; 2024-2030 (US$ Billion)
Figure 20: The US RSV Vaccine Market by End User; 2024 (Percentage, %)
Figure 21: The US Adult RSV Vaccine Market by Value; 2024-2030 (US$ Billion)
Figure 22: The US Adult RSV Vaccine Market Product Type by Value; 2024-2030 (US$ Million)
Figure 23: The US Maternal & Pediatric RSV Vaccine Market by Value; 2024-2030 (US$ Million)
Figure 24: The US Maternal & Pediatric RSV Vaccine Market Product Type by Value; 2024-2030 (US$ Million)
Figure 25: The US RSV Antibody Market by Value; 2024-2030 (US$ Million)
Figure 26: The US RSV Antibody Market Product Type by Value; 2024-2030 (US$ Million)
Figure 27: Europe RSV Vaccine And Antibody Market by Value; 2024-2030 (US$ Billion)
Figure 28: Europe RSV Vaccine Market by Value; 2024-2030 (US$ Billion)
Figure 29: Europe RSV Vaccine Market by End User; 2024 (Percentage, %)
Figure 30: Europe Adult RSV Vaccine Market by Value; 2024-2030 (US$ Billion)
Figure 31: Europe Adult RSV Vaccine Market Product Type by Value; 2024-2030 (US$ Million)
Figure 32: Europe Maternal & Pediatric RSV Vaccine Market by Value; 2024-2030 (US$ Million)
Figure 33: Europe Maternal & Pediatric RSV Vaccine Market Product Type by Value; 2024-2030 (US$ Million)
Figure 34: Europe RSV Antibody Market by Value; 2024-2030 (US$ Million)
Figure 35: Europe RSV Antibody Market Product Type by Value; 2024-2030 (US$ Million)
Figure 36: ROW RSV Vaccine And Market by Value; 2024-2030 (US$ Billion)
Figure 37: ROW RSV Vaccine Market by Value; 2024-2030 (US$ Billion)
Figure 38: ROW RSV Vaccine Market by End User; 2024 (Percentage, %)
Figure 39: ROW Adult RSV Vaccine Market by Value; 2024-2030 (US$ Million)
Figure 40: ROW Adult RSV Vaccine Market Product Type by Value; 2024-2030 (US$ Million)
Figure 41: ROW Maternal & Pediatric RSV Vaccine Market by Value; 2024-2030 (US$ Million
Figure 42: ROW Maternal & Pediatric RSV Vaccine Market Product Type by Value; 2024-2030 (US$ Million)
Figure 43: ROW RSV Antibody Market by Value; 2024-2030 (US$ Million)
Figure 44: ROW RSV Antibody Market Product Type by Value; 2024-2030 (US$ Million)
Figure 45: Global Urban Population as a Share of Total Population; 2016, 2021 & 2050 (Percentage, %)
Figure 46: Global Percentage Of Population Aged 65 Years Or Over; 2022, 2030 & 2050 (Percentage, %)
Figure 47: The US Health Consumption Expenditure as a Percentage of GDP; 2016-2022 (Percentage, %)
Figure 48: Global Market Size for Artificial Intelligence in Healthcare; 2021-2030 (US $Billion)
Figure 49: GlaxoSmithKline Plc Sales by Products; 2022 (Percentage, %)
Figure 50: Merck & Co., Inc. Sales by Segments; 2022 (Percentage, %)
Figure 51: Pfizer Inc. Revenue by Segment; 2022 (Percentage,%)
Figure 52: AstraZeneca Total Revenue by Disease Areas; 2022 (Percentage, %)
Figure 53: Sanofi S.A. Net Sales by Segments; 2022 (Percentage,%)
Figure 54: Moderna Inc. Total Revenue by Geographic Area; 2022 (Percentage,%)
Table 1: RSV V/S COVID-19
Table 2: Global RSV Vaccine And Antibody Snapshot
Table 3 : Global RSV Vaccine And Antibody Players By Market Share; 2024-2030 (Percentage, %)
Table 4: Global RSV Vaccine And Antibody Market: Current Landscape
